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Abstract
Background: Abnormal α-synuclein aggregation and deposition is the pathological hallmark 
of Parkinson’s disease and dementia with Lewy bodies, but is also found in Alzheimer’s
disease. Therefore, there is a gaining interest in α-Synuclein in cerebrospinal fluid (CSF) as 
potential biomarker for these neurodegenerative diseases.
Objectives: To broaden the available choices of α-Synuclein measurement in CSF, we 
developed and validated a new, independent assay for detecting total α-Synuclein.
Methods: This novel ELISA uses commercially available antibodies and is based on
electrochemiluminescence technology. The assay protocol is straightforward with short and
simple incubation steps and requires only small amounts of CSF. We validated this assay for
precision, parallelism, dilution linearity, specificity, and spike recovery. We further compared
it to the newly validated α-Synuclein assay from BioLegend by analyzing a set of 50 CSF 
samples with both assays.
Results: The new assay quantifies α-Synuclein in CSF with a lower limit of detection of 
0.0363 ng/ml and shows no cross-reactivity with human - and -Synuclein. Results of
dilution linearity, parallelism, spike recovery and precision classify this assay as well suited
for α-Synuclein detection in human CSF samples. 
Conclusion: We present a novel assay based on freely available components to quantify total
α-Synuclein in CSF as an additional method for α-Synuclein as a biomarker in 
neurodegenerative diseases. The assay convinces with its simple and convenient protocol
paired with high sensitivity.
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Introduction
There is a frequent overlap of symptoms between Parkinson’s disease (PD), dementia with
Lewy bodies (DLB) and other parkinsonian disorders as well as between DLB, Alzheimer’s
disease (AD) and other dementias. This results in diagnostic difficulties that can result in
faulty or delayed diagnosis. This is of critical importance in the treatment of these diseases
and highlights the need of diagnostic and prognostic biomarkers.
α-Synuclein plays a prominent role in the pathogenesis of several severe neurodegenerative 
diseases, and PD and DLB in particular.1,2 It is the main component of Lewy bodies,3 which
are intraneuronal deposits of insoluble protein, a feature that is also present in up to 60% of
patients with sporadic AD.4
Aggregation and deposition of α-Synuclein is most likely caused by an imbalance in the 
equilibrium between synthesis, aggregation and clearance.2 The extent of oligomerisation and
fibrillation in the brain could influence the amount of total α-Synuclein present in 
cerebrospinal fluid (CSF), just like the reduction in β-amyloid (Aβ42 and the Aβ42/Aβ42) in 
CSF likely is due to retention of the peptide as aggregates in the brain in AD (Blennow,
2014). Thus, findings in CSF might reflect the pathologic events in the brains of patients with
abnormal α-Synuclein. 
Accordingly, α-Synuclein in CSF has been proposed as biomarker for PD,5-8_ENREF_5 DLB,9
and AD.10 Both encouraging and negative findings have been reported. In PD, α-Synuclein 
levels have been repeatedly reported to be decreased as compared to controls although some
studies could not confirm this.6 Further, a meta-analysis including 7 studies indicates that α-
Synuclein distinguishes DLB from AD.9
The majority of studies employ modifications of an in-house assay first described by Tokuda
et al.11 or an in-house assay developed by Mollenhauer at al.12, the successor of which just
page 4
recently became commercially available and validated. 13,14,15 To uncover α-Synuclein’s 
biomarker potential, further independent, accessible and well validated methods are needed.
As a new approach to quantify total α-Synuclein in CSF we therefore developed an 
electrochemiluminescence detection ELISA test entirely based on freely available
components and validated it according to the newest guidelines.16
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Materials and Methods
Developed detection method
Plate preparations: Wells of a 96-well high binding capacity plate (#L15XB, Meso Scale
Discovery) were spot-coated with 5µl of 15µg/ml anti-α-Synuclein antibody (#610787, BD 
Transduction Laboratories) in DPBS (#SH30028, HyClone) and allowed to adsorb for 24hrs
at room temperature (uncovered). The wells were then directly blocked with 150µl of 1%
skim milk (#1.15363, Merck KGaA) and 1% BSA (#A7030, Sigma-Aldrich) in PBS-
Tween 20 (0.05%, Merck KGaA) pH 7.4 (PBS-T) overnight at +4°C for use the following
day. Blocking solution was freshly prepared, agitated for 15min to completely dissolve BSA
and centrifuged at 2000g for 10min prior to use.
Assay procedure: CSF samples were diluted 1:2 with PBS-Tween 20 (0.1%) pH 7.4 to
achieve a final concentration of 0.05% Tween 20. A 4-fold serial dilution of recombinant α-
Synuclein (#S-1001-1, rPeptide) in PBS-T (0.05%) ranging from 0.0098ng/ml to 160ng/ml
served as calibrator. All steps were performed at room temperature and plates were sealed
during incubation.
Blocking solution was aspirated and wells were washed 3x with 150µl PBS-T (0.05%). 25µl
of controls, calibrators, and diluted samples were added to the wells and incubated for 1h with
gentle shaking (400rpm). Plates were washed 4x with 150µl PBS-T (0.05%) and incubated
with 25µl of 2µg/ml anti-α/β/γ-Synuclein (FL-140, #sc-10717, Santa Cruz Biotechnology), 
diluted in blocking solution for 1h (400rpm). Wells were washed 4x with 150µl PBS-T
(0.05%) and incubated with 25µl of 1µg/ml goat anti-rabbit antibody with Sulfo-tag
(#R32AB-5, Meso Scale Discovery) in blocking solution for 1h in the dark (400rpm). Plates
were washed 4x with 150µl PBS-T (0.05%) and read on a Sector Imager 2400 using 150µl
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2X Read buffer (#R92TC-1, Meso Scale Discovery, diluted from 4X with deionized water)
per well. All samples were run in duplicate.
CSF samples
The CSF samples were leftover aliquots from clinical routine, following a procedure
approved by the Ethics Committee of University of Gothenburg. All samples were also de-
identified in accordance with the Swedish biobanking law. All CSF samples were centrifuged
at 2,000 x g for 10 minutes before frozen in polypropylene tubes at -80°C. Aliquots of 500 µl
were stored in 1.7 ml and aliquots of 20 µl for precision tests were stored in 0.5 ml tubes.
Samples were subjected to one freeze-thaw event for aliquotation purposes prior to analysis
Validation of detection method
The chosen design of the assay validation experiments was based on recently published
guidelines and methods. 14,16 Both pools of CSF and CSF from single donors were used in the
validation experiments. CSF numbering is consistent throughout the validation experiments.
Lower Limit of Quantification (LLOQ): 16 replicates of the blank, the calibrator diluent
(0.05% PBS-T), were analyzed and the LLOQ was determined as the concentration
corresponding to the signal of the mean of these 16 replicates plus 10 times the SD.
Specificity for a-Synuclein: The detection antibody FL-140 recognizes α-, β-, and γ-
Synuclein. Therefore, serial dilutions of recombinant β- and γ-Synuclein (#SNB2001, 
#SNG2001, ATGen) in PBS-T (0.05%) ranging from 0.0156 to 40 ng/ml were tested to prove
specificity to α-Synuclein. 
Parallelism: Four CSF samples were diluted 1:2 in PBS-Tween 20 (0.1%, final concentration
in diluted sample: 0.05% Tween 20) and then further diluted in 1:2 steps in PBS-T (0.05%)
until a final dilution of 1:16. All dilutions and the undiluted CSF samples were analyzed in
duplicates.
page 7
Dilution Linearity: Four CSF samples were spiked with calibrator to a final concentration
approx. 100-times higher than the highest α-Synuclein concentration of the CSF used in the 
validation procedures and serial diluted 1:2 in PBS-T (0.05%). The first dilution was again
made with PBS-T (0.1%). All dilutions and the undiluted, spiked CSF samples were analyzed
in duplicates.
Spike-recovery: Five samples of 1:2 diluted CSF (PBS-T, final conc. 0.05% Tween 20) were
spiked with calibrator to a final concentration of 10, 0.625, and 0.039 ng/ml in addition to the
endogenous levels by adding 1 volume of calibrator to 15 volumes of CSF. Endogenous α-
Synuclein concentration was determined by analyzing CSF spiked with calibrator diluent in
the same manner. Endogenous α-Synuclein concentration was subtracted from concentration 
in samples with spike before calculation of recovery.
Precision: Six CSF samples were divided into aliquots in small volume polypropylene tubes
and frozen at -80 °C. On five different occasions, two to ten aliquots were analyzed each, in
total 25 for each CSF. Precision replicates had been frozen individually and were diluted
independently on the assay day. For the precision experiments different lots of Sulfotag-
antibody and assay plates were used.
CSF measurements
Hemoglobin measurement: Samples were analyzed for hemoglobin content using a
commercial kit (#E88-135, Bethyl Laboratories). Samples with hemoglobin levels higher than
300 ng/ml were excluded from analysis. Samples with available erythrocyte count (collected
in Sweden) were not analyzed for hemoglobin. All of these samples had a count of below 100
erythrocytes perµL.
-Synuclein measurement with the here described assay: 50 CSF samples were analyzed
using the protocol described above. Samples were diluted by adding 1 volume of sample to 1
volume PBS-T (0.1%) in polypropylene predilution plates (#P-96-450R-C, Axygen),
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centrifuged at 300 x g for 1 min, and mixed by shaking at 600 rpm for 5 mins. All samples
were run in duplicate on the same day and reagents from the same lots were used.
Comparison with the α-Synuclein assay from BioLegend 
An identical set of sample aliquots was analyzed with the commercial assay from BioLegend
(#844101, BioLegend) at the Clinical Neurochemistry Laboratory at the Sahlgrenska
University Hospital, Sweden, according to the manufacturer’s instructions.
Antibodies
We tested different combinations of antibodies 211 (Santa Cruz Biotechnology, #sc-12767),
FL-140 (Santa Cruz Biotechnology, #sc-10717), anti-α-Synuclein clone 42 (#610787, BD 
Transduction Laboratories), MJFR1 (#ab138501, Abcam), anti-α-Synuclein (#SAB1300799, 
Sigma Aldrich), and anti-α-Synuclein (#NBP1-67696, Novus Biologicals). 
Data analysis
Standards and samples were analyzed in duplicates. Standard curve fitting (4 parameter
logistic fit), plotting of calibrator curve and calculation of concentrations were performed
using the Mesoscale Discovery Workbench software. All other calculations were performed
in Microsoft Excel. Coefficients of variation (CV) < 20% for repetitive measurements and <
15% for intra-assay measurements were considered as acceptable. For dilution linearity and
parallelism, absolute values were normalized to values of the assay-recommended 1:2 dilution
for better comparability. Intra- and inter-assay CVs for precision samples were calculated
according to ISO 5725-2 using the Excel sheet provided by U. Andreasson as supplementary
file to 16.
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Results
Validation of the assay for the detection of α-Synuclein in human CSF 
To establish this assay, we first searched for antibody combinations that work well to detect
recombinant α-Synuclein. The combination of antibodies anti-α-Synuclein clone 42 and FL-
140 gave the best results. Thus we optimized this assay further and validated it for the
following characteristics:
Lower limit of quantification
The novel assay detects α-Synuclein with a LLOQ of 0.0363 ng/ml in CSF. We did not 
determine the upper limit of quantification because α-Synuclein levels in CSF were generally 
below 3 ng/ml, which is far below the end of the linear range of the assay (≤ 160 ng/ml, r2 >
0.99, n = 6, Fig. 1). Extending the calibrator to 640 ng/ml resulted in a plateauing of the signal
above 160 ng/ml (not shown). The mean signal of 16 replicates of calibrator diluent was
164.3  4.29 units (CV = 2.6%) and significantly below the lowest signal of CSF samples
(317 units).
Specificity for α-Synuclein 
β- and γ-Synuclein are structurally related to α-Synuclein, and the detection antibody (FL-
140, St. Cruz Biotechnologies) recognizes both α-, β- and γ-Synuclein. However, this assay 
showed no cross-reactivity with recombinant human β- and γ-Synuclein (Fig. 1), which 
proves specificity to α-Synuclein. 
Parallelism
Parallelism was within accepted criteria (CV < 15%) for all tested dilutions in all four CSF
samples. α-Synuclein concentrations were normalized to the standard assay dilution of 1:2 
(Fig. 2a).
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Dilution linearity
After spiking with high calibrator of approximately 100 times of typical CSF α-Synuclein 
concentrations, CV values were well within accepted criteria (< 15%) for all tested dilutions
in all four CSF samples. Values are normalized to the standard assay dilution of 1:2 (Fig. 2b).
Spike recovery
Four CSF samples were spiked with three different concentrations of calibrator ranging from
below, within and above the range of typical CSF concentrations (0.0391, 0.625, and 10
ng/ml). After subtraction of the endogenous α-Synuclein concentrations, the recovery rate was 
between 80.4% and 81.7%. Only the CV value for the recovery of the lowest spike, which
was 0.0391 ng/ml, was outside the accepted criteria (25.5%) (Table 2).
Precision
Intra-assay CVs (repeatability) for the six CSF tested were between 9.9% and 15.8%. The
inter-assay CVs (intermediate precision) were between 14% and 21.2% (Table 1). Intra-assay
CV improved with history of performed assays.
Comparison with commercial assay from BioLegend
Recently, the validation of a previously academic assay that now is commercially available
(#844101, BioLegend) was published.14,15 We therefore analyzed an identical set of 50
samples on both assays. Samples were randomly distributed over 5 assay plates. The CV
values of the three implemented quality control samples were lower than 6% between plates.
We found a strong correlation between the two assays as assessed by Spearman rho (r =
0.718, n = 50, P < 0.001, Fig. 3).
page 11
Discussion
Over the past years, quantification of α-Synuclein in CSF and its potential as biomarker in 
neurodegenerative diseases has gained a growing interest. To explore the suitability of
biomarker candidates, validated and accessible detection techniques are essential. For α-
Synuclein, several detection methods, both academic and commercial, are described, but to
our knowledge, only the assay from BioLegend has been comprehensively validated.14 We
therefore developed and validated an electrochemiluminescence detection ELISA based
entirely on freely available components with a simple and convenient protocol. Then we
compared the assay to the commercially available, validated α-Synuclein ELISA from 
BioLegend using a set of 50 CSF samples.
The chosen design of validation experiments was based on recently published guidelines,16
and the recent validation of the BioLegend assay.14 We decided to include determination of
LLOQ, specificity, parallelism, dilution linearity, spike recovery, and precision. A
comprehensive set of pre-analytical confounders has been already tested by Kruse et al.,14
who demonstrated that α-Synuclein CSF levels are not affected by delay of freezing, 
centrifugation regime, and a diverse range of storage conditions, concluding that α-Synuclein 
is a very stable protein.14 These tests were therefore not repeated. Due to lack of certified
reference material (CRM), Trueness, i.e. concordance between the reference value of the
CRM and actual measurements, could not be addressed.
The LLOQ of 0.0363 ng/ml was significantly lower than the amounts of α-Synuclein 
observed in all tested samples and CSF pools used in validation experiments. Also, the
antibody tandem showed no cross reactivity with - or -Synuclein. This means that this assay
is well suitable for the detection of α-Synuclein in CSF. 
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For α-Synuclein several isoforms exist. However, the capture antibody has been successfully 
used by us and others17 to detect specifically α-Synuclein-140 from various human samples 
and tissues,18 thus we conclude that this assay detects only the 140 aa form of α-Synuclein. 
The assay passed the criteria for parallelism and dilution linearity. The CV value for the spike
recovery for the lowest spike was 25.5%. This may be explained by the very low addition of
exogenous α-Synuclein to the endogenous levels of α-Synuclein. Nevertheless, spike recovery 
was about 80-82% for all spikes and thus within the accepted criteria16 of 80-120%. CV
values of the moderate and high spike were below 10%. Precision inter- and intra-assay CV
values were within accepted criteria with two exceptions where limits were slightly exceeded
(cf. Table 1). We observed that precision improved with history of performed assays and
therefore recommend training of staff with the assay-specific sample handling prior to analyze
clinical samples in addition to the general recommendation of run control application.
Accordingly, the plate-to-plate precision of the five plates used for the comparison with the
BioLegend assay was much improved and below 6%.
The high correlation between our assay and the BioLegend assay may indicate that the two
methods detect similar alterations in CSF levels of α-Synuclein. The observed correlation of > 
0.7 (Spearman rho) is in the same magnitude as previously seen for two commercial assays to
detect A42 in human CSF samples.19
Given the excellent assay performance, we will employ this assay with clinical cohorts to
further determine the possibility of using α-Synuclein as a diagnostic or prognostic biomarker. 
We also intend to adapt our assay for the detection of phosphorylated (predominant species in
Lewy bodies 20) and oligomeric forms (assumed to be the main toxic form 21) of α-Synuclein 
as those forms, alone or combined with total α-Synuclein, may further enhance the diagnostic 
and prognostic performance of α-Synuclein measures in CSF. 
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Conclusion
We validated a novel assay, which reliably detects α-Synuclein in human CSF. The assay has 
several strengths including a convenient protocol and high sensitivity paired with need of only
small amounts of CSF.
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Table 1
Repeatability and Intermediate precision
Name Mean conc. (ng/ml) Repeatability (%CVr) Intermediate precision (%CVRw)
CSF 1 0.312 10.0 19.8
CSF 2 0.220 11.5 16.5
CSF 3 0.308 11.3 14.0
CSF 4 0.388 15.8 18.2
CSF 5 0.469 12.8 17.8
CSF 6 0.521 9.9 21.2
Mean - 11.9 17.9
Table 2
Spike Recovery
Spike (ng/ml)
0.0391 0.625 10
Name Recovery (%)
CSF 1 108,1 77,6 79
CSF 2 79,4 93,2 82,6
CSF 3 94,9 74,9 81,4
CSF 5 59,4 80,7 86,2
CSF 6 63,4 75,5 79,4
Mean 81,04 80,38 81,72
SD 20,65 7,52 2,90
CV 25,49 9,35 3,55
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Fig 1
Figure 1: Superimposition of six calibrator curves that were used in the validation
experiments. Two representative curves for - and -Synuclein, respectively, were included.
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Fig. 2a
Parallelism
Fig. 2b
Dilution linearity
Figure 2. A): Parallelism of serially diluted CSF samples. B) Dilution linearity of serially
diluted CSF samples after spiking with high concentration of α-Synuclein. 
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Fig. 3
Correlation of a-Synuclein measurements
Figure 3: Correlation of α-Synuclein levels determined by the presented and the BioLegend 
assay.
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Figure captions
Figure 1: Superimposition of six calibrator curves that were used in the validation
experiments. Two representative curves for - and -Synuclein, respectively, were included.
Figure 2a: Parallelism of serially diluted CSF samples.
Figure 2b: Dilution linearity of serially diluted CSF samples after spiking with high
concentration of α-Synuclein. 
Figure 3: Correlation of α-Synuclein levels determined by the presented and the BioLegend 
assay.
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